MapLight Therapeutics, Inc. 8-K

What Happened

• On June 22, 2026 MapLight Therapeutics, Inc. filed a Form 8-K disclosing that it will hold a conference call to discuss topline results from IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder. The company also issued a press release the same day announcing the IRIS trial results. The presentation for the call is furnished as Exhibit 99.1 and the press release as Exhibit 99.2 to the filing.

Key Details

• Trial: IRIS (ML-004-002), a Phase 2 study of ML-004 in autism spectrum disorder.
• Disclosure date: June 22, 2026 — conference call and press release issued on that date.
• Materials: Company presentation (Exhibit 99.1) and press release (Exhibit 99.2) accompany the 8-K.

Why It Matters

• Topline Phase 2 results are a major clinical milestone that can influence the company’s development path and investor expectations for ML-004. Investors should review the presentation and press release and listen to the conference call for details on efficacy, safety, and next steps announced by the company.